Table1. Weighted rates of use of respiratory medications and influenza vaccine among BOLD sites.
| Any Bronchodilators or any Inhaled Corticosteroids | Influenza vaccine | |||
|---|---|---|---|---|
| BOLD sites | Population weighted rate1 (%, SE) | Standardised rate for clinical need2 (%, N3) | Population weighted rate1 (%, SE) | Standardised rate for clinical need2 (%, N3) |
| High Income Countries | ||||
| Bergen, Norway | 8.9 (1.1) | 32.2 (4) | 21.7 (1.5) | 38.8 (7) |
| Hannover, Germany | 8.4 (1.1) | 52.9 (9) | 37.9 (2.0) | 42.2 (4) |
| Krakow, Poland | 7.7 (1.1) | 37.6 (8) | 7.2 (1.0) | 12.4 (1) |
| Lexington, USA | 22.9 (1.9) | 56.9 (25) | 38.5 (2.2) | 39.8 (20) |
| Lisbon, Portugal | 9.3 (0.9) | 32.4 (8) | 25.8 (2.2) | 27.3 (7) |
| London, England | 18.2 (2.2) | 58.1 (19) | 40.2 (2.5) | 60.9 (23) |
| Maastricht, Netherlands | 13.1 (1.6) | 45.5 (15) | 41.4 (2.2) | 50.4 (16) |
| Reykjavik, Iceland | 15.6 (1.3) | 51.1 (9) | 32.9 (1.7) | 35.2 (7) |
| Salzburg, Austria | 5.5 (0.7) | 36.4 (14) | 18.9 (1.2) | 24.4 (4) |
| Sydney, Australia | 17.4 (1.6) | 52.9 (10) | 33.4 (2.0) | 40.1 (6) |
| Tartu, Estonia | 4.3 (0.8) | 30.7 (2) | 6.2 (1.0) | 6.2 (0) |
| Uppsala, Sweden | 15.2 (1.5) | 47.5 (5) | 21.0 (1.8) | 15.3 (2) |
| Vancouver, Canada | 16.8 (1.3) | 50.2 (13) | 45.9 (1.7) | 52.5 (13) |
| Low and Middle Income Countries | ||||
| Adana, Turkey | 4.9 (0.7) | 16.0 (8) | 2.1 (0.6) | 1.5 (1) |
| Cape Town, South Africa | 7.8 (0.9) | 26.7 (18) | 4.8 (0.8) | 2.5 (2) |
| Ile-Ife, Nigeria | 0.6 (0.3) | 25.6 (1) | 0.6 (0.3) | 0.2 (0) |
| Guangzhou, China | 1.1 (0.4) | 27.2 (2) | 0.5 (0.3) | 0.5 (0) |
| Manila, Philippines | 3.7 (0.7) | 37.0 (7) | 0.8 (0.4) | 1.0 (0) |
| Mumbai, India | 3.9 (1.5) | 35.7 (3) | 0.4 (0.3) | 4.9 (1) |
| Nampicuan&Talugtug, Philippines | 3.6 (0.8) | 11.3 (6) | 0.3 (0.2) | 2.7 (1) |
| Pune, India | 1.2 (0.3) | 20.4 (3) | 0.0 (0.0) | 0.0 (0) |
| Sousse, Tunisia | 3.5 (0.8) | 30.6 (5) | 56.6 (3.2) | 69.7 (9) |
| Srinagar, India | 2.4 (0.6) | 41.9 (4) | 0.0 (0.0) | 0.0 (0) |
Population estimated rate of use, weighted for survey design at each site (US, Canada and Iceland had simple random samples, China, Austria, Germany, Poland, Norway, Australia, England, Sweden, The Netherlands, Estonia, and Pune had stratified random samples, S.Africa had a cluster random sample, Turkey, Philippines, Mumbai, Portugal, Tunisia, Srinagar and Nigeria had stratified cluster samples)
Directly standardised rate of use among standard studied groups of adults aged 50-69 years, with spirometrically confirmed COPD stage 2+ with wheeze or with dyspnoea stage 2+., weighted for survey design at each site.
N refers to the number of individuals in the sample who fall under the standard definition, based on whom the weighted results reported were made.